Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 86.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 121,560 shares of the biopharmaceutical company’s stock after acquiring an additional 56,461 shares during the period. Natixis Advisors LLC owned about 0.10% of Halozyme Therapeutics worth $6,958,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Congress Asset Management Co. grew its stake in shares of Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB grew its stake in Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares in the last quarter. Epoch Investment Partners Inc. grew its stake in Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Halozyme Therapeutics by 9.7% in the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock worth $43,002,000 after purchasing an additional 72,544 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $39,988,802.96. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 60,000 shares of company stock worth $3,425,000. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 0.1 %

Halozyme Therapeutics stock opened at $45.70 on Friday. The company’s fifty day simple moving average is $55.15 and its 200-day simple moving average is $53.48. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The stock has a market cap of $5.81 billion, a P/E ratio of 15.13, a P/E/G ratio of 0.41 and a beta of 1.29.

Wall Street Analyst Weigh In

HALO has been the subject of a number of research reports. JMP Securities lifted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Morgan Stanley lifted their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Sandler lifted their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. TD Cowen lifted their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Benchmark restated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.